We conducted a systematic review and network meta-analysis to examine comparative efficacy and tolerability of pharmacologic interventions for pulmonary arterial hypertension (PAH).
Pulmonary arterial hypertension (PAH) or World Health Organization (WHO) group 1 pulmonary hypertension is a progressive disease associated with significant morbidity and a 5% to 15% annual mortality rate. [1] [2] [3] In recent years, a number of drug classes to treat PAH have been approved for clinical use. These include endothelin receptor antagonists (ERA), phosphodiesterase-5 inhibitors (PDE5i), parenteral and nonparenteral prostacyclins, a soluble guanylate cyclase stimulator, and a prostacyclin-receptor agonist. Although randomized controlled trials (RCTs) have compared individual drugs to conventional therapy or placebo, head-to-head comparisons of different pharmacologic agents are limited. Conventional meta-analyses are limited by estimates between two interventions compared directly with each other, precluding assessment of comparative efficacy and safety of all available interventions. [4] [5] [6] [7] Hence, evidence regarding the best treatment, either alone or in combination, is limited, leaving such decisions to individual clinical judgment. 8, 9 A network meta-analysis approach can bridge this gap and guide both clinical decision-making and future research. 10, 11 Therefore, we performed a network meta-analysis combining direct and indirect evidence to evaluate comparative efficacy and safety of all US Food and Drug Administration (FDA)-approved pharmacologic interventions, alone or in combination, in patients with PAH.
Methods
This systematic review is reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement for network meta-analysis and was conducted following a priori established protocol (PROSPERO-CRD42016036803). 12, 13 We followed the International Society for Pharmacoeconomics and Outcomes Research approach on interpreting network meta-analyses for health-care decision-making. 14, 15 We used Grading of Recommendations Assessment, Development and Evaluation (GRADE) to appraise quality of evidence. 16 
Selection Criteria
We included phase II or phase III RCTs with a minimum of 8 weeks of follow-up, meeting the following criteria: (1) Patients were primarily adults with symptomatic PAH (group 1 pulmonary hypertension). Some trials studied subjects 12 years of age and older and were included; however, trials restricted to pediatric or neonatal patients were excluded. (2) Interventions included all FDA-approved drugs specifically for PAH, including ERA (bosentan, ambrisentan, macitentan), PDE5i (sildenafil, tadalafil), oral/inhaled (PO/INH) prostanoids (treprostinil, iloprost), IV/subcutaneous (SC) prostanoids (epoprostenol, treprostinil), the soluble guanylate cyclase simulator riociguat, and the selective prostacyclin-receptor agonist selexipag, alone or in combination, administered for 8 weeks or longer. ( 3) The comparator consisted of another active agent, placebo, or conventional therapy. (4) Outcomes included trials reporting any of the efficacy outcomes (clinical worsening, hospitalization, mortality, and improvement in functional class or 6-min walk distance [6MWD]). As in prior studies, 4, 7 RCTs in which a PAH therapy was initiated on the background of another PAH-specific cointervention were included as trials of active agents against placebo, and nature and rates of background therapy in each arm were examined narratively. Detailed exclusion criteria are presented in e-Appendix 1, Methods.
Search Strategy
The search strategy was designed and conducted by an experienced medical librarian with input from study investigators. Multiple databases were searched for RCTs of pharmacologic therapy for PAH until March 3, 2016 (details in e-Appendix 1, Methods). Figure 1 shows study selection and e- Table 1 details the reasons for exclusion of randomized trials.
Data Abstraction and Quality Assessment
Data were abstracted independently by two reviewers using a standardized data abstraction form, and discrepancies were resolved after mutual agreement and discussion with a third reviewer. The risk of bias for individual studies was assessed using the Cochrane Risk of Bias assessment tool. 17 
Outcomes Assessed
We defined five major efficacy outcomes and one safety outcome. The efficacy outcomes were selected to reflect two aspects of PAH therapy. First, improvements in patient morbidity and mortality were assessed by reduction in (1) study-defined clinical worsening, representing a composite of death, PAH-related hospitalization, lung transplantation, atrial septostomy, initiation of rescue therapy and deterioration of functional class or worsening of 6MWD, varying across studies (e- improvement by $ 1 functional class from baseline (New York Heart Association [NYHA] or WHO) and (2) change in 6MWD (from baseline). For 6MWD, the a priori minimal clinically important difference was an increase of $ 33 meters from baseline, associated with lower mortality and improved functional status. 18 Tolerability was assessed by medication-related adverse events leading to drug discontinuation. For studies reporting outcomes at multiple time points, outcomes were preferentially assessed at 16 AE 4 weeks (e-Appendix 1, Methods).
Statistical Analysis
First, we performed direct meta-analysis for all treatment comparisons using the DerSimonian-Laird random-effects approach, incorporating within-study and between-study heterogeneity. 19 We assessed statistical heterogeneity using the I 2 statistic, with values > 50% indicating substantial heterogeneity. 20 To assess for publication bias, we examined the network funnel plot for evidence of small study effects. 21, 22 Second, we conducted network meta-analysis using a multivariate random-effects meta-regression. 23, 24 Categorical outcomes were reported as risk ratio (RR), and continuous outcome (6MWD) was reported as weighted mean difference (WMD), with their corresponding 95% CIs. For categorical outcomes, an estimate for the absolute effect size was additionally obtained by multiplying the RR for each agent with the median placebo response rate for that outcome. 25 Differences between direct and indirect evidence were assessed using tests of model consistency by including trial design as an additional covariate in the model. 26 Third, we ranked drugs in order of their efficacy and tolerability using the surface under the cumulative ranking (SUCRA). 27 Finally, to address between-study heterogeneity, we performed multiple sensitivity analyses that were restricted to trials (1) with a minimum follow-up duration $ 12 weeks, (2) published after the year 2000, and (3) with no or < 20% of study participants receiving background therapy. Further details are presented in e-Appendix 1, Methods.
Quality of Evidence
Using the GRADE framework, we rated the quality of evidence of estimates derived from network meta-analysis from high quality to very low quality (e- Table 3 ) for efficacy outcomes, ie, clinical worsening and improvement in functional class. 16 For this, evidence was rated down for risk of bias, indirectness of evidence, heterogeneity, imprecision, and publication bias. Further details are presented in e-Appendix 1, Methods.
Identification

Screening
Eligibility
Included
Records identified through database searching (n = 16,236)
Additional records identified through other sources (n = 20)
Records after duplicates and pre-1990 studies removed (including manual search for duplicates) (n = 12,392)
Records screened based on title/abstract (n = 1,011) Figure 1 shows study selection. Figure 2 demonstrates all available direct comparisons across outcomes (outcome-specific networks) (e- Fig 1, A-F ).
Characteristics and Quality of Included Studies
Overall, trials included 6,565 participants (range, 18-1,156 participants). (Fig 3) . Here, riociguat and ERA þ PDE5i were ranked highest (SUCRA, 0.89 and 0.86, respectively), followed by PDE5i (SUCRA, 0.68) and ERA (SUCRA, 0.46) in reducing clinical worsening (e- Table 4 ). For the hospitalization outcome, only the ERA þ PDE5i combination was associated with improvement compared with placebo (RR, 0.19; 95% CI, 0.06-0.64). For all-cause mortality, events rates were low across trials, and between-group differences were not significant (Table 3) . (Fig 3) .
Here IV/SC prostanoids were associated with the highest rank for improvement in functional class over all other active agents (SUCRA, 0.99). For improving 6MWD, when compared with placebo, the combination of ERAþ PDE5i was ranked highest (SUCRA, 0.96; WMD, 54.1 m; 95% CI, 29.8-8. 
journal.publications.chestnet.org (Table 3 ), but no agent consistently achieved the a priori defined minimal clinically important difference of 33m (all CIs crossed this value).
Adverse Events Leading to Discontinuation
Low adverse-event-related medication discontinuation was examined as a marker for higher tolerability. Twenty-six RCTs reported data on this outcome. Direct meta-analysis is presented in e- Figure 8 and e-Appendix 1, Results. In network meta-analysis for this outcome, the highest SUCRA ranking was achieved by riociguat (0.92), followed by PDE5i (0.80), ERA þ PDE5i (0.62), and ERA (0.56) (higher SUCRA corresponds to lower adverse events) (e- Table 3 ).
The results of our sensitivity analyses restricted to trials with follow-up $ 12 weeks, recent publication (after 2000), or those with < 20% patients receiving background therapy did not differ substantially from our primary analysis (e- Table 5 ). There was no evidence for small study effects based on funnel plot asymmetry, suggesting absence of publication bias (e- Fig 9) . There was no evidence of network inconsistency (P > .05 for all comparisons).
Quality of Evidence
The GRADE quality of evidence for the primary efficacy outcomes of clinical worsening and improvement in functional class is summarized in e- Table 6 . Placebo comparisons were rated down for indirectness due to differences in study population (background therapy and PAH subtypes) as well as the definition of outcomes (for clinical worsening). Head-to-head comparisons were further downgraded for indirectness and imprecision due to limited head-to-head trials and wide CIs, respectively. Moderate-quality evidence supported the use of ERA, PDE5i, their combination, riociguat, and selexipag for reducing clinical worsening in PAH. The The column treatment is compared with the row treatment (ie, row treatment is reference for each comparison). Numbers in bold represent statistically significant results. RR ¼ risk ratio, WMD ¼ weighted mean difference. See Table 1 legend for expansion of other abbreviations.
journal.publications.chestnet.org combination of ERA þ PDE5i was supported by highquality and moderate-quality evidence in the comparison against monotherapy with ERA and PDE5i, respectively. Other head-to-head comparisons were supported by lowto very low-quality evidence. For the functional class outcome, moderate-quality evidence supported ERA, ERA þ PDE5i, IV/SC prostanoids, and selexipag in improving functional class over placebo, whereas lowquality evidence supported the use of PDE5i and riociguat. In head-to-head comparisons, most agents were supported by only low-quality evidence.
Discussion
In this network meta-analysis combining evidence from 31 RCTs including 6,565 patients with PAH and using the GRADE framework to appraise the quality of evidence, we made several important observations. First, treatment with riociguat, ERA, PDE5i, and the combination of ERA and PDE5i compared with placebo was associated with significant reduction in risk of clinical worsening, supported by a low to moderate quality of evidence. Although riociguat had the strongest effect, the point estimate was based on a single study. Second, parenteral (IV/SC) prostanoids, ERA, PDE5i, and the ERA þ PDE5i combination were associated with significant improvement in WHO/NYHA functional class compared with placebo, with most placebo comparisons supported by moderate-quality evidence. The same agents led to significant improvements in 6MWD, another marker of exercise capacity with prognostic implications. 58 Third, only the combination of ERA þ PDE5i was associated with a lower likelihood of PAH-related hospitalization, but the data were derived from a single trial. Fourth, none of the studied agents was associated with reduced mortality. Finally, nonparenteral (PO/INH) prostanoids and selexipag were more likely to be discontinued secondary to adverse events.
There is limited evidence to guide choice of therapy between different agents, with only two head-to-head trials comparing different drug classes against each other. 56, 57 The current clinical guidelines derive data from individual drug studies and single-agent metaanalyses. 58, 59 However, the direct meta-analyses in the published literature synthesized evidence informing about either the pooled effect of drug therapy on relevant outcomes 4, 7 Clinical worsening, defined differently across trials to include a combination of hospitalization, mortality, and a need for invasive therapy, has increasingly been reported as a primary outcome in recent randomized trials. In our study, we found that ERA, PDE5i, their combination, and riociguat are associated with reduced clinical worsening. Although riociguat was associated with the highest probability of reducing clinical worsening, this effect was supported by low-quality evidence. The combination of ERA þ PDE5i had the second highest probability in improving this outcome. PAH-related hospitalization, a component of clinical worsening, was also studied as a stand-alone outcome, and these two outcomes may therefore be correlated. Although the clinical worsening outcome for most individual studies followed the direction of the hospitalization outcome (e- Figs 3, 4) , it cannot be confirmed if reported rates of clinical worsening were driven by hospitalization events given the limited reporting of other individual components of clinical worsening. The impact of parenteral prostanoids on clinical worsening remains to be studied, since none of the trials evaluated this outcome.
PAH-related hospitalization and mortality were not significant in most placebo-drug and drug-drug comparisons, other than a reduction in hospitalizations with the combination of ERA þ PDE5i. For the mortality outcome, although prior studies have suggested a reduction in mortality with overall pharmacologic therapy 7 and with some prostacyclin analogues, 4 mortality events across trials were low, and we did not find a significant difference for these comparisons. The included studies were likely underpowered for assessing mortality, particularly given their short duration of follow-up and the use of time-tofirst-event of clinical worsening as a primary end point in recent trials that potentially led to censoring of patients earlier in the course of disease. Long-term follow-up in registries may allow further future analyses of this important end point.
Since current guidelines emphasize initiation of therapy with worsening functional capacity (defined by functional class II or worse), measures of improving exercise capacity were commonly reported. For these outcomes, we found that parenteral prostanoids were associated with the highest probability of achieving improvement in functional class compared with placebo, as well as with individual agents, including ERA, PDE5i, riociguat, selexipag, and the combination of ERA þ PDE5i. Compared with placebo, ERA, PDE5i, and their combination improved functional class significantly, supported by moderate-quality evidence. The combination of ERA þ PDE5i was also associated with the highest probability of improving 6MWD, an outcome that has been suggested to be associated with patient prognosis. Individual components of this combination, as well as parenteral prostanoids, were associated with significant improvement in 6MWD; however, the previously suggested minimal clinically significant improvement for 6MWD was not consistently achieved for this outcome. On the contrary, nonparenteral prostanoids did not improve functional status or measures of morbidity. Furthermore, medication safety and tolerability, as assessed by adverse events leading to discontinuation, were least favorable for nonparenteral prostanoids, consistent with the results of a recent meta-analysis. 60 Hence, this provides evidence against their role as primary therapy in the management of PAH. Their suggested role as "ancillary therapy" in clinical guidelines would need to be further investigated. Next, although riociguat was associated with improved rates of clinical worsening, it did not have a significant effect on either functional class or 6MWD and may not be sufficient therapy in patients with decompensated disease with poor functional status.
Our findings must be interpreted in light of the following limitations. First, most results in our analysis are supported by low-to moderate-quality evidence, which, by definition, suggests that future studies are likely to affect our confidence in these estimates (e- Table 3 ). Differences in participant characteristics, cointerventions, and outcome assessment downgraded the quality of evidence. Although such conceptual heterogeneity is a limitation inherent to any metaanalysis, in PAH, variability in the characteristics of enrolled patients and definitions for important outcomes (clinical worsening) makes interpretation of evidence challenging for clinicians and investigators. Moreover, temporal evolution of PAH trials over time further adds to this between-study variation. In our study, we attempted to minimize heterogeneity by establishing strict inclusion criteria for the trials and assessing outcomes at prespecified time points. We also performed sensitivity analyses in more homogeneous subgroups, specifically including only contemporary trials and those with limited or no background PAH therapy. Although these sensitivity analyses were consistent with our primary findings, uniform criteria for inclusion and outcome assessment for future trials are necessary to generate high-quality evidence. Second, because of the limited number of head-to-head trials, comparisons between active agents were mainly derived from lower-quality indirect evidence and should therefore be interpreted with caution. Future comparative efficacy trials are, therefore, warranted to make definitive conclusions. Third, similar to previous PAH meta-analyses, 4, 7, 60, 61 our analysis is somewhat limited by the small number of RCTs available for each drug; we had to combine the effect of multiple agents in a drug class. It is possible that the efficacy of agents is drug specific rather than class specific. Next, the readership should be careful about "ecologic fallacy," since conclusions derived from group-level data may not be applicable to individual patients. Fifth, multiple ORs produced for the various pairwise comparisons in network meta-analysis may be considered multiple testing and therefore may be at risk for type 1 error and represent chance findings. There are no established techniques to address this; however, the consistency among significant findings would suggest that such effects may be limited. Finally, since most contemporary trials were conducted with patients receiving one or more agents as background therapy, it was not possible to perform indirect comparisons among all direct classes with agents only as monotherapy.
Conclusions
Among oral agents, ERA, PDE5i, and their combination are associated with improvement in patient morbidity (both clinical worsening and hospitalization) and functional status. Other approved agents are associated with improvement in different measures of efficacy, and selection of an agent may be guided by the most desired outcome for each particular patient. Our findings are limited by few head-to-head trials and differences in reporting across trials. We therefore emphasize the need for future studies focusing on head-to-head comparisons with uniform enrollment and outcome assessment to improve comparability and produce higher-quality evidence that informs clinical decision-making.
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